Introduction
Leishmaniasis is a major public health problem in tropical and subtropical countries. It is endemic in 64 countries, and 90% of the world's cases are reported in India, Bangladesh, Nepal, Sudan, and Brazil. The disease may be asymptomatic or subclinical, or may cause a severe disease called visceral leishmaniasis (VL) or kala-azar. Post-kala-azar dermal leishmaniasis (PKDL) is a complication of VL characterized by severe rashes and skin lesions in mostly young patients who have recovered from VL (Elshafie et al., 2007) .
Leishmania-infected patients can show clinical and laboratory features that mimic autoimmune hepatitis, primary biliary cirrhosis and systemic lupus erythematosus (SLE) and wrongly diagnosed as having such diseases (Sakkas et al., 2008) , and like rheumatic diseases Leishmania-infected patients have high levels of circulating immune complexes (CIC) and autoantibodies like rheumatoid factor and antinuclear antibodies (ANA) (Elshafie et al., 2007; Sakkas et al., 2008; Åhlin et al., 2015) . We also recently described that Leishmania donovani-infected subjects can present with positive reactions against cyclic citrullinated peptide 2 (anti-CCP2), an autoantibody otherwise highly specific for rheumatoid arthritis (RA). The anti-CCP2 reactivity was in the low positive range, in contrast to Sudanese anti-CCP2 positive RA patients who presented with very high anti-CCP2 levels (Åhlin et al., 2015) , in agreement with previous findings in Caucasian RA patients. Anti-CCP2 antibodies react with citrulline residues in proteins or peptides where arginine residues have been post-translationally modified, and when we compared the anti-CCP2 reactivities with parallel plates coated with identical peptides except that the citrulline residues had been exchanged with the native arginine residues we found that the Leishmania-infected patients reacted equally well with both plates, whereas the Sudanese RA patient showed citrulline-specific reactivity. We concluded that the Leishmania-infected patients reacted in the anti-CCP2 test in a way that was independent of citrullination of the peptides (Åhlin et al., 2015) .
In this report we present further investigations in RA-associated autoantibodies in L donovani-infected subjects. Due to our interest in immunity against the joint-specific protein collagen type II (CII) in RA (Mullazehi et al., 2007 (Mullazehi et al., , 2012 we investigated anti-CII antibodies in Sudanese subjects. As we found elevated anti-CII reactivity in Leishmania-infected patients as compared to controls, we again performed investigations with control plates, and also this time showed higher reactivity in the control plates than in CII-coated plates. Intriguingly, almost all patients with highly active leishmaniasis showed such false reactivity. As our control plates in this recent experiment were only blocked, our results raise general concerns about ELISA measurement of autoantibodies in tropical Africa and perhaps also elsewhere where Leishmania infection or other highly inflammatory infections appear.
Methods

Study subjects
The study was carried out at Tabarakalla rural hospital in Gedarif state in Northern Sudan, which it is endemic for L. donovani, and where the main Leishmania vector is Phlebotomaus orientalis (Elshafie et al., 2007) . A detailed clinical history and examination were obtained from each studied patient. Subjects were questioned about their ethnic, and geographic origin and were examined for clinical manifestations of VL and PKDL. A general clinical examination was conducted with particular reference to hepatomegaly, splenomegaly and lymph node involvements. All suspected patients were investigated for malaria; those with malaria infection were excluded. For diagnosis an inguinal lymph node aspiration was performed on those clinically suspected of having VL (i.e., all individuals with any of the following clinical findings: fever for N2 months, left upper quadrant pain, lymphadenopathy, splenomegaly, or wasting). All individuals with clinically suspected VL but with negative results on inguinal lymph node aspiration were subjected to bone marrow aspiration aiming to seek for L. donovani bodies for VL confirmation.
Leishmania-infected patients included 62 VL patients (20 females and 42 males; age median (mean): 24 (26) years; range 3-73), 44 PKDL patients (13 females and 31 males; age 23 (20) years; range 3-27) and 49 healthy controls without any disease complaints from Tabarakalla village (26 females and 23 males; age 22 (20) years; range 3-45). Severely ill patients with VL admitted to the Tabarakalla hospital for hospitalization were classified as acute VL (n = 15). Patients not severely ill and treated as outpatients with daily injections of sodium stibogluconate were classified as sub-acute VL (n = 47).
Venous blood drawn from patients and healthy controls was separated by centrifugation and frozen in liquid nitrogen within 2 h of sampling and transported frozen in liquid nitrogen until analyzed in Uppsala. Data on 274 Swedish early RA patient sampled at the time of diagnosis that was made within 1 year after first symptoms, as previously described (Mullazehi et al., 2007) and using exactly the same anti-CII ELISA are included for comparison.
Ethical approval for this study was obtained from the ethical committee from the Ministry of Health in Khartoum and Gedarif State, Sudan. Informed consent was obtained from all the adults who participated in the study. For younger children, consent was obtained from their parents. For the Swedish RA patients the ethical approval was obtained from the Ethical Committee at Karolinska Institutet, Stockholm. Ethical approval to conduct immune complex and autoantibody studies has also been obtained from the Ethical Board in Uppsala.
Anti-CII ELISA
The indirect ELISA was performed as in our previous publications (Mullazehi et al., 2007 (Mullazehi et al., , 2012 . High-binding ELISA plates (Nunc MaxiSorp, Nunc, Roskilde, Denmark) were coated with human native CII (Chondrex, Redmond, WA) at a concentration of 5 μg/ml in PBS at 4°C overnight. Preliminary titrations had showed CII concentrations at or above 2.5 μg/ml to yield optimal results. The coating solution was thereafter discarded and the plate blocked with 1% IgG-depleted ELISA grade bovine serum albumin (Sigma, Stockholm, Sweden) in PBS (PBS-BSA); for 1 h at room temperature on a shaker. After washing with PBS + 0.05% Tween, serum samples (1:101 dilution) and a standard curve derived from an RA serum with very high anti-CII levels diluted in PBS-BSA were added to the plates for 2 h at room temperature. After further washing, an alkaline phosphatase-conjugated goat anti-human γ chain specific antibody (dilution 1:10,000; Jackson ImmunoResearch, Cambridgeshire, UK) was added at room temperature for 1 h on a shaker. To minimize unwanted interactions, the antibody used was F(ab′)2 and had been adsorbed to exhibit minimal crossreactivity with bovine immunoglobulins that might remain in the blocking solution. After three more washings with PBS-BSA the reaction was developed using 4-nitrophenyl phosphate disodium tablets (Sigma) in diethanolamine buffer and the optical density read at 405 nm after 60 min. The cutoff 29 U/ml was set at the 95th percentile among 100 Swedish healthy blood donors as in previous studies (Mullazehi et al., 2007) . Two internal controls were run on all ELISA plates in parallel to unknown samples, and only plates with internal control values within a predetermined range were accepted. The internal control close to the cutoff had an intra-assay CV of 15%.
Patients with positive reactions were investigated a second time with comparison of OD values in CII coated/BSA blocked wells in parallel to wells only blocked with BSA in duplicates and on the same plate. We classified samples with higher OD in the CII-coated wells as compared to the BSA coated wells as true positive and those with the highest OD in the wells containing only BSA as false positive. Sera with anti-CII levels below the cutoff 29 AU/ml were denoted as negative and were not further investigated with parallel BSA wells. This approach is in agreement with our previous use of the ELISA (Mullazehi et al., 2007 (Mullazehi et al., , 2012 .
Anti-CCP2 and anti-C1q-binding CIC ELISA measurements
Anti-CCP2 was measured using the Immunoscan RA Mark 2 assay (Euro-Diagnostica, Malmö, Sweden). In accordance with manufacturer's instructions 25 U/ml was used as a cut-off. The kit provides no standard points below 25 U/ml, and the ELISA standard curve was extended by serial dilution down to 3.13 AU/ml to yield quantitative data also in the low range. C1q-binding CIC were measured with ELISA as previously described (Åhlin et al., 2015) .
Statistics
Analyses with the Shapiro-Wilk W test and probability (QQ) plots showed non-normal distribution of anti-CII levels among Sudanese controls, PKDL and VL patients, both for all data, as well as after exclusion of true anti-CII positive results. As we previously have shown anti-CII to be non-normally distributed also in RA patients (Mullazehi et al., 2012) we used non-parametric tests. For the comparison between two groups, we used the non-parametric Mann-Whitney's U test for unpaired samples. To estimate correlations between variables, we used the Spearman non-parametric test. p values b 0.05 were regarded as significant. All calculations were made by means of the software JMP 11 for Mac.
Results
High anti-CII levels in Leishmania-infected patients
The median (mean) anti-CII levels among the Sudanese healthy controls were 16 (21) AU/ml. For the PKDL and VL patients the corresponding figures were 28(43) and 48(58) AU/ml, respectively (Fig. 1 ). Levels were significantly higher among PKDL (p = 0.0004) and VL (p b 0001) patients as compared to Sudanese healthy controls. Using the cutoff previously defined for Sweden, 26% (13/49) of the Sudanese controls, 48% (21/44) of the PKDL patients and 65% (40/62) of the VL patients showed reactivity against anti-CII (Fig. 2) .
The median (mean) values for Swedish RA patients was 12(55), and 10% (27/274) showed anti-CII reactivity. As previously described (Mullazehi et al., 2012) a small outlier subgroup of the Swedish RA patients showed very high levels of CII (9/274) patients with levels between 470 and 3522) not seen on our Leishmania cohort. The proportions of CII positivity were also higher in subjects with Leishmania infection when compared to the Swedish RA patients (p b 0001 compared to both PKDL and VL patients; Fig. 1). 3.2. Leishmaniasis patients, especially acutely ill VL patients, exhibit false positive anti-CII reactivity in ELISA After further evaluation of the anti-CII positive subjects with only blocked control plates we found that the majority of anti-CII positive Leishmania-infected subjects exhibited false positive reactivity. False positive anti-CII reactivity increased with increasing inflammatory activity in a stepladder fashion from Sudanese healthy controls to PKDL via subacute VL and finally to acute VL where almost all subjects 93% (14/15) show a false positive anti-CII reactivity. Among the Swedish RA patients 1.5% (4/274) exhibited false positive anti-CII reactivity, very similar to the Sudanese control subjects 2% (1/49). The distributions of negative, true positive and false positive anti-CII reactivity in the investigated groups using the Swedish cutoff are graphically depicted in Figs. 1 and 2 . Also when using a higher cut-off based on the 95th percentile among the Sudanese controls (80.4 U/ml) we get a parallel relative increase in false reactivity when we move from Sudanese healthy controls (0/49, 0%) to PKDL (2/44, 4.5%), subacute VL (8/47, 17%) and acute VL (8/15, 53%; data not shown).
Non-related ELISA results correlate strongly in visceral leishmaniasis patients
To investigate whether the high degree of false positive anti-CII reactions especially in the VL group might be a universal finding in ELISA tests, we studied the correlation between the commercial ELISA in the different groups. As we hypothesized that especially false positive reactivities might show a high degree of correlation among patients with high inflammatory activity we first calculated correlation without excluding subjects with true positive results and thereafter re-calculated this correlation only for subjects with negative or false positive anti-CII results as shown in Fig. 3 . The correlation coefficients increased after exclusion of true positive reactions for both Leishmaniainfected groups, and the largest correlation coefficient was found for VL patients. Thus the false anti-CII reactivity showed the strongest correlation to results obtained from an unrelated commercial ELISA for VL patients, the group with the highest percentage of false positive anti-CII reactions, and the correlation coefficients increased when true positive anti-CII reactions had been excluded in PKDL and VL patients, both groups with inflammatory disease. For subjects not infected with Leishmania, Sudanese healthy controls and Swedish RA patients, there was no significant correlation between anti-CCP2 and anti-CII after exclusion of true positives. For the Sudanese subjects, this comparison could only be made for anti-CCP2 variation below the cutoff, as sera from the (false) anti-CCP2 positive Leishmania-infected subjects had been exhausted in the experiments described in (Åhlin et al., 2015) .
No correlation between circulating immune complexes and false positive anti-CII reactivities among Leishmania-infected patients
As CIC levels are increased in Leishmania patients, and as CIC might be a cause of false positive reactions in ELISA we correlated CIC and anti-CII levels after exclusion of true positive anti-CII samples. For all Sudanese subjects (healthy controls, PKDL and VL patients) there was a significant correlation (r = 0.53, p b 0.0001, n = 123), whereas no significant correlation was seen for any of the groups investigated individually (controls: r = 0.26, p = 0.12, n = 37; PKDL: r = 0.36, p = 0.30, n = 35; all VL subjects: r = 0.26, p = 0.071, n = 51; subacute VL: r = 0.14, p = 0.36, n = 36, acute VL: r = 0.37, p = 0.22, n = 15). Due to lack of serum, a number of Sudanese subjects were not investigated for CIC levels.
Discussion
In a previous report we defined that Leishmania-infected subjects from an endemic area in Sudan possess a false positive anti-CCP2 reactivities in ELISA, as the patients reacted equally well against ELISA wells with citrullinated peptides or with arginine-containing control peptides (Åhlin et al., 2015) . In the current study we extend these studies to anti-CII, another RA-associated autoantibody. Also here Leishmania-infected patients react stronger to control wells. But as the control wells in our current study only are blocked with the same blocking agent as used in the CII-coated wells and this blocking solution is common to many widely used ELISA protocols, the findings might be valid for any ELISA using a simple blocking system, and raises general concerns about the detection of antibodies with ELISA in Leishmania-infected subjects and possibly also in other diseases with high inflammatory activity. Both in our previous report (Åhlin et al., 2015 ) and in our current study (Fig. 1) , the false ELISA reactivities found in Leishmania-infected patients are found in the low positive range, whereas positive control groups with RA patients show strong and true positive reactions against anti-CCP2 and anti-CII, respectively. The findings might be applicable also to commercial ELISA systems as we show a high degree of correlation between anti-CCP2 and anti-CII especially in patients with VL, the most inflammatory form of leishmaniasis. None of the autoantibodies anti-CCP2 or anti-CII have any known association to Leishmania infection, and when we exclude the low number of true anti-CII positive reactivities and thus focus on the false reactive patients, the significant correlation between the two unrelated autoantibodies increase in both groups of Leishmania-infected patients. On the contrary, there is no such correlation between false anti-CII reactivity and anti-CCP2 in the control groups of Sudanese healthy individuals or Swedish RA patients. In fact, anti-CII and anti-CCP2 represent two clinically distinct phenotypes when investigated in the same RA cohort (Mullazehi et al., 2007; Rönnelid et al., 2005) .
In our previous paper, the false positive anti-CCP2 reactivity was only marginally diminished after depletion of immune complexes (Åhlin et al., 2015) , but we did not have enough samples left for parallel investigations for anti-CII. We anyhow think that the false anti-CII reactivity determined in Leishmania-infected subjects is probably not related to immune complexes, as none of the Sudanese subgroups showed any correlation between CIC and false anti-CII reactivity when analyzed separately. The fact that these variables correlated when all Sudanese subjects were analyzed together is probably a group effect. Both measures are increased in Leishmania infected patients as compared to in Sudanese controls, as we have shown previously for CIC (Åhlin et al., 2015) and in this paper for false positive anti-CII reactivity.
Our findings should be considered when handling the diagnostics of Leishmania-infected subjects in tropical areas like Sudan. Previous reports and our own experience (AE) state that the clinical presentation of Leishmania infection can be misclassified as autoimmune diseases like autoimmune hepatitis or SLE, including autoantibodies like antinuclear antibodies (ANA), IgM rheumatoid factor, anti-DNA and anticardiolipin (Sakkas et al., 2008) . In that clinical setting physicians might request autoantibody testing by ELISA to confirm the clinical suspicion of autoimmunity. If the requested ELISA present the kind of general false reactivity described in this report, misdiagnosis and wrong management in subjects infected with L. donovani infection may ensue.
Also previous papers have reported false ELSA antibody reactivity in tropical and developing areas, concerning malaria serology (Ghosh et al., 2001) , anti-neutrophil cytoplasmic antibodies (ANCA) (Ghosh et al., 2008) and Chlamydia serology (Miyashita et al., 2008) . In our paper we extend these findings to encompass two independent ELISA systems for measurement of autoantibodies not related to Leishmaniainfected patients. We show that there is a strong correlation between the reactivities measured with these two ELISAs, especially when the few true anti-CII positive samples had been excluded, and thus that the finding of false reactivity is not dependent on specific autoantibody reactivities, but on the ELISA format per se.
Before performing this study we only had access to Swedish anti-CII data, and the definition of which samples should be subjected to a second round of comparison with only blocked wells was based on the reference range derived from Swedish controls. As the general anti-CII levels among healthy controls living in the Sudanese village of Tabarakalla turned out to be higher than among Swedish blood donors, we have calculated a second cutoff derived from Sudanese controls, and thereby we have defined individuals between the two cutoff lines as either true or false positive (Fig. 1) . In this purely technical report including individuals from both countries we have chosen to keep the definition of positivity based on Swedish data, but as we describe in Section 3.2, the general findings are the same using a cutoff based on Tabarakalla controls (Figs. 1 and 2) . In a clinically oriented paper, one should of course always interpret autoantibody data in relation to a control population that is clinically relevant to the study in question.
In our view, indirect ELISA or other solid phase immune assay tests for antibodies to be used in areas with Leishmania infection might be accompanied by simultaneous evaluation of reactivity in control wells without the target antigen. This is not currently the case, see e.g. (Abass et al., 2013) . Very few commercial solid phase antibody systems use such individual control wells, to our knowledge the only exception being the anti-SA test for a subgroup of anti-citrullinated protein/peptide antibodies (ACPA) delivered by the company Euroimmun. An obvious drawback of this approach suggested by us is that the number of samples to be tested in each ELISA plate is diminished by 50% as haft of the ELISA plates will be used for control wells.
As other reports have shown false reactivity in ELISA tests also in other tropical diseases (Ghosh et al., 2001 (Ghosh et al., , 2008 ; Miyashita et al., Fig. 3 . Correlation between anti-CII and anti-CCP2 levels for a.) Sudanese healthy controls, b.) PKDL patients, c.) VL patients and d.) Swedish RA patients. The correlation coefficients r s and significance levels were calculated with the Spearman rank correlation test. Correlation data for all subjects are shown before the slash signs, and after exclusion of subjects with true positive anti-CII after the slash signs. Filled circles represent negative and true positive results for CII and stars represent false positive reactions with higher OD in BSA wells than in CII wells. Fifteen Swedish RA patients with very high anti-CCP2 or anti-CII levels are not shown in d.) but included in the statistical calculations.
2008) such recommendations to use individual control wells might be extended to other infectious disease settings and also to other continents than Africa. One example is the false positive anti-CCP2 reactivity in hepatitis C-infected subjects in USA where the authors used only blocked ELISA plates as individual controls and reported that the binding was caused by nonspecific binding to plastic (Wener et al., 2004) . The findings might not be limited to indirect antibody ELISA systems, as nonspecific binding to the matrix including e.g. blocking agent and plastic might appear also in direct ELISA and sandwich ELISA systems. These hypotheses need validation in further studies.
Conclusion
Our data imply that sera from Leishmania-infected subjects often react non-specifically in ELISA and we therefore suggest that individual-specific control wells should be included for antibody measurements in areas endemic for leishmaniasis. These suggestions might also be applicable to other geographical areas or patients groups with high incidence of inflammatory and infectious diseases.
